Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial
Authors:
- Jacobus LubsenJLJacobus Lubsen
- Gilbert WagenerGWGilbert Wagener
- Bridget-Anne KirwanBKBridget-Anne Kirwan
- Sophie De BrouwerSBSophie De Brouwer
- Philip A Poole-WilsonPPPhilip A Poole-Wilson
- ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) investigatorsAIACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) investigators
- 1 March 2005
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 23 (3) , 641-648
Abstract
To examine the effects of nifedipine GITS on clinical outcome in patients with concurrent stable angina and hypertension. Data from the double-blind placebo-controlled ACTION trial was stratified for hypertension (blood pressure ≥ 140/90 mmHg), at baseline. A total of 52% of 7665 ACTION patients were hypertensive. Some 80% were on a β blocker; hypertensives were more often treated with other blood pressure-lowering drugs. Mean baseline blood pressure was 122/74 mmHg among normotensives and 151/85 mmHg among hypertensives. Follow-up blood pressures were reduced by nifedipine (P < 0.001) on the average by 3.9/2.4 and 6.6/3.5 mmHg among normotensives and hypertensives, respectively. Nifedipine GITS significantly (P < 0.05) reduced the combined incidence of all-cause mortality, myocardial infarction, refractory angina, heart failure, stroke and peripheral revascularization by 13% in hypertensives only. Nifedipine significantly reduced the incidence of any stroke or transient ischemic attack by almost 30% in both subgroups and the need for coronary angiography by 21% in normotensives and 16% in hypertensives. Among hypertensives, the incidence of new overt heart failure was significantly reduced by 38% and of debilitating stroke by 33%. Among normotensives, the need for coronary bypass grafting was significantly reduced by 32%. Nifedipine did not affect all-cause death, cardiovascular death and myocardial infarction in either normo- or hypertensives, but increased the need for peripheral revascularization. The salutary effects of the addition of nifedipine GITS to the basic regimen of patients with concurrent stable symptomatic coronary artery disease and hypertension emphasize the need for blood pressure control.Keywords
This publication has 21 references indexed in Scilit:
- Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trialsThe Lancet, 2003
- Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)The Lancet, 2000
- Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) studyThe Lancet, 2000
- Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 studyThe Lancet, 1999
- Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertensionThe Lancet, 1997
- Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party.BMJ, 1992
- Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)The Lancet, 1991
- Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic HypertensionJAMA, 1991
- MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party.BMJ, 1985
- MORTALITY AND MORBIDITY RESULTS FROM THE EUROPEAN WORKING PARTY ON HIGH BLOOD PRESSURE IN THE ELDERLY TRIAL*1, *2The Lancet, 1985